A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
The antibody-drug conjugate (ADC) is one of the most rapidly growing next generation antibody therapies used in oncology, autoimmunity and chronic inflammatory diseases. ADC is consisted of monoclonal antibody conjugated via chemical linker with highly cytotoxic small molecules, called payloads. Due to the rising prevalence of cancer and population aging, there is a consistent unmet needs on novel therapeutics for patients where the traditional antibody therapy does not work. With thedoi:10.17480/psk.2018.62.3.158 fatcat:37pmt2n75jfxxpbjypcdjucpvy